SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
A nationwide cohort study found lower rates of cardiorenal complications and hepatic decompensation
-
By
-
Henry Thomas
-
March 10, 2026
-
Clinical Scorecard: SGLT2 Inhibitors Linked to Better Outcomes in Diabetes and Cirrhosis
At a Glance
| Category | Detail |
|---|
| Condition | Type 2 Diabetes and Cirrhosis |
| Key Mechanisms | SGLT2 inhibitors lower risks of kidney, cardiovascular, and hepatic complications. |
| Target Population | Patients with type 2 diabetes and cirrhosis. |
| Care Setting | Nationwide cohort study in Taiwan. |
Key Highlights
- Lower risk of end-stage kidney disease with SGLT2 inhibitors.
- Reduced incidence of acute kidney injury compared to DPP-4 inhibitors.
- Fewer major adverse cardiovascular events in patients on SGLT2 inhibitors.
- Decreased hepatic decompensation events among SGLT2 inhibitor users.
- Study included 24,259 patients with diverse causes of cirrhosis.
Guideline-Based Recommendations
Diagnosis
- Consider SGLT2 inhibitors for patients with type 2 diabetes and cirrhosis.
Management
- Monitor kidney function and cardiovascular health in patients receiving SGLT2 inhibitors.
Monitoring & Follow-up
- Track outcomes related to kidney, cardiovascular, and hepatic health during treatment.
Risks
- Be aware of potential residual confounding and limitations in laboratory data.
Patient & Prescribing Data
Patients with type 2 diabetes and cirrhosis, average age 64.7 years.
SGLT2 inhibitors may provide significant benefits over DPP-4 inhibitors.
Clinical Best Practices
- Utilize SGLT2 inhibitors in appropriate patients to reduce complications.
- Conduct regular follow-ups to assess treatment efficacy and safety.
References
